کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3254024 1207172 2014 20 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Medical treatment of obesity: The past, the present and the future
ترجمه فارسی عنوان
درمان های پزشکی چاقی: گذشته، حال و آینده
کلمات کلیدی
اورلستات، داروهای سروتونرژیک، داروهای سمیپومومیتیک، آگونیست های پپتید 1 مانند گلوکاگون، درمان ترکیبی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی غدد درون ریز، دیابت و متابولیسم
چکیده انگلیسی

Medications for the treatment of obesity began to appear in the late 19th and early 20th century. Amphetamine-addiction led to the search for similar drugs without addictive properties. Four sympathomimetic drugs currently approved in the US arose from this search, but may not be approved elsewhere. When noradrenergic drugs were combined with serotonergic drugs, additional weight loss was induced. At present there are three drugs (orlistat, phentermine/topiramate and lorcaserin) approved for long-term use and four sympathomimetic drugs approved by the US FDA for short-term treatment of obesity. Leptin produced in fat cells and glucagon-like peptide-1, a gastrointestinal hormone, provide a new molecular basis for treatment of obesity. New classes of agents acting on the melanocortin system in the brain or mimicking GLP-1 have been tried with variable success. Combination therapy can substantially increase weight loss; a promising approach for the future.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Gastroenterology - Volume 28, Issue 4, August 2014, Pages 665–684
نویسندگان
,